Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TEVA ITALIA SRL

Home Clinical Trial Sponsors and OrganizationsTEVA ITALIA SRL

TEVA ITALIA SRL

ACTIVE

VIA RODARI 9, Como, Italywww.tevaitalia.itSubsidiary251–500 employeesEstablished: 1901-01-01

Part of Teva Pharmaceutical Industries Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1901

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1

33.3%

Trial Status Distribution

Active, not recruiting

3

100.0%

Clinical Trials

Trials sponsored by this organization (3)

A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.

Active, not recruiting

Aug 20127 participants

A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and of a reference arm of Interferon β-1a (Avonex) in a rater-blinded design - Bravo

Active, not recruiting

Mar 20081,200 participants

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS). - Allegro

Active, not recruiting

Mar 20081,000 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals
News

Back to Organizations